Feasibility of Utilizing EPIC-CP to Guide Symptom Management for Clinically Localized Prostate Cancer Patients Undergoing Hypofractionated Radiotherapy

Abstract

Utilization of patient-reported outcome measures (PROMs) to guide symptom management during radiation therapy has shown to be more sensitive to changes in health status and might detect the exact onset of the toxic effects of radiotherapy more accurately than clinician-reported outcomes. The Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) is a validated 16-item, diseasespecific PROM that targets the unique needs of men with prostate cancer (PCa) and evaluates the five HRQOL domains of urinary incontinence, urinary irritation/obstruction, bowel related symptoms, sexual dysfunction and hormonal symptoms.